There are 2949 resources available
977TiP - Role of microbiome as a biomarker in locoregionally-advanced oropharyngeal squamous cell carcinoma 2 (ROMA LA-OPSCC2)
Presenter: Geoffrey Watson
Session: E-Poster Display
Resources:
Abstract
978TiP - Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase I/II trial
Presenter: Pierluigi Bonomo
Session: E-Poster Display
Resources:
Abstract
979TiP - POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck
Presenter: Sharon Forsyth
Session: E-Poster Display
Resources:
Abstract
980TiP - VOICE- head and neck cancer patient journey’s health literacy needs and experience: Patient, caregivers and healthcare professionals’ perspectives
Presenter: Claudia Vieira
Session: E-Poster Display
Resources:
Abstract
982P - Comparison of donafenib and sorafenib as advanced hepatocellular carcinoma first-line treatments: Subgroup analysis of an open-label, randomized, parallel-controlled, multicentre phase II/III trial
Presenter: Shukui Qin
Session: E-Poster Display
Resources:
Abstract
983P - Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial
Presenter: Jianming Xu
Session: E-Poster Display
Resources:
Abstract
984P - Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma with major portal vein tumor thrombosis (Vp3/4): A randomized phase II trial
Presenter: Xiaodong Wang
Session: E-Poster Display
Resources:
Abstract
985P - A phase II study of camrelizumab for advanced hepatocellular carcinoma: Two-year outcomes and continued treatment beyond RECIST-defined progression
Presenter: Zhenggang Ren
Session: E-Poster Display
Resources:
Abstract
986P - Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)
Presenter: Aiwu Ruth He
Session: E-Poster Display
Resources:
Abstract
987P - A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC)
Presenter: Lin Shen
Session: E-Poster Display
Resources:
Abstract